SOUTH SAN FRANCISCO, Calif. / Feb 02, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2024 ended December 31, 2023.
"We're starting fiscal 2024 off strong with record revenue of $71.5 million for the first fiscal quarter, coming in above our projection, with a gross margin of 40.5%," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "In SynBio, after a limited launch of Express Genes in November, we expanded the offering to include midi and Maxi preps at Express speed and over time, we expect this offering will allow us to both expand our share of market and convert the Maker's Market of researchers who make their own genes into DNA buyers."
Dr. Leproust continued, "NGS had a strong quarter, with our top ten customers accounting for 44% of NGS revenue. As we move through the year, we plan to introduce new products and differentiated solutions to our customers and remain laser focused on revenue growth, margin expansion and financial discipline as we progress on our path to profitability."
FISCAL 2024 FIRST QUARTER FINANCIAL RESULTS
Recent Highlights:
Updated Fiscal 2024 Financial Guidance
The following statements are based on Twist’s current expectations for fiscal 2024, including the second quarter of fiscal 2024. The following statements are forward-looking, and actual results could differ materially depending on market conditions and the factors set forth under “Forward-Looking Statements” below.
For the full fiscal year 2024, Twist provided the following updated financial guidance:
For the second quarter of fiscal year 2024, Twist provided the following financial guidance:
Conference Call Information
The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its financial results and provide an update on the company’s business. The conference call will be webcast live through the Investor Relations section under the “Company” tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company’s Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.
About Twist Bioscience
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube | Instagram
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, projections under the heading “Updated Fiscal 2024 Financial Guidance” statements regarding future growth and expansion, timing of the development of data storage solutions, revenue growth, estimated annual revenues, ability and timing to achieve profitability and ability to increase gross margins and Twist Bioscience’s other expectations regarding its future operations plans and financial performance, introduction of new products, and newly announced partnerships. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 21, 2023 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Twist Bioscience Corporation Condensed Consolidated Statements of Operations (Unaudited) (in thousands) | ||||||||
|
| Three months ended December 31, | ||||||
(In thousands, except per share data) |
|
| 2023 |
|
|
| 2022 |
|
Revenues |
| $ | 71,498 |
|
| $ | 54,243 |
|
Operating expenses: |
|
|
|
| ||||
Cost of revenues |
| $ | 42,536 |
|
| $ | 29,442 |
|
Research and development |
|
| 23,099 |
|
|
| 31,242 |
|
Selling, general and administrative |
|
| 52,840 |
|
|
| 42,324 |
|
Change in fair value of contingent considerations and holdbacks |
|
| — |
|
|
| (4,135 | ) |
Total operating expenses |
| $ | 118,475 |
|
| $ | 98,873 |
|
Loss from operations |
| $ | (46,977 | ) |
| $ | (44,630 | ) |
Interest income |
|
| 4,120 |
|
|
| 3,040 |
|
Interest expense |
|
| — |
|
|
| (1 | ) |
Other income (expense), net |
|
| (31 | ) |
|
| (157 | ) |
Income tax (provision) / benefit |
|
| (120 | ) |
|
| (76 | ) |
Net loss attributable to common stockholders |
| $ | (43,008 | ) |
| $ | (41,824 | ) |
Net loss per share attributable to common stockholders—basic and diluted |
| $ | (0.75 | ) |
| $ | (0.74 | ) |
Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted |
|
| 57,497 |
|
|
| 56,444 |
|
Twist Bioscience Corporation Condensed Consolidated Balance Sheets (Unaudited) (in thousands) | ||||||||
(In thousands) |
| December 31, |
| September 30, | ||||
Assets |
|
|
|
| ||||
Current assets: |
|
|
|
| ||||
Cash and cash equivalents |
| $ | 266,269 |
| $ | 286,470 | ||
Short-term investments |
|
| 44,875 |
|
| 49,943 | ||
Accounts receivable, net |
|
| 35,354 |
|
| 44,064 | ||
Inventories |
|
| 30,863 |
|
| 32,063 | ||
Prepaid expenses and other current assets |
|
| 12,870 |
|
| 11,716 | ||
Total current assets |
| $ | 390,231 |
| $ | 424,256 | ||
Property and equipment, net |
|
| 126,225 |
|
| 131,830 | ||
Operating lease right-of-use assets |
|
| 69,093 |
|
| 71,531 | ||
Other non-current assets |
|
| 147,266 |
|
| 148,786 | ||
Total assets |
| $ | 732,815 |
| $ | 776,403 | ||
Liabilities and stockholders’ equity |
|
|
|
| ||||
Current liabilities: |
|
|
|
| ||||
Accounts payable |
| $ | 9,256 |
| $ | 14,052 | ||
Accrued expenses |
|
| 13,959 |
|
| 10,754 | ||
Accrued compensation |
|
| 20,787 |
|
| 25,818 | ||
Current portion of operating lease liability |
|
| 14,808 |
|
| 14,896 | ||
Other current liabilities |
|
| 6,418 |
|
| 7,803 | ||
Total current liabilities |
| $ | 65,228 |
| $ | 73,323 | ||
Operating lease liability, net of current portion |
|
| 77,070 |
|
| 79,173 | ||
Other non-current liabilities |
|
| 475 |
|
| 475 | ||
Total liabilities |
| $ | 142,773 |
| $ | 152,971 | ||
Total stockholders’ equity |
| $ | 590,042 |
| $ | 623,432 | ||
Total liabilities and stockholders’ equity |
| $ | 732,815 |
| $ | 776,403 | ||
| Last Trade: | US$40.36 |
| Daily Change: | -2.82 -6.53 |
| Daily Volume: | 590,686 |
| Market Cap: | US$2.360B |
October 30, 2024 August 05, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
